公开(公告)号：WO02070507A3

公开(公告)日：2002-11-21

申请号：PCT/US0204541

申请日：2002-01-16

Applicant: ABBOTT LAB

Inventor： KYM PHILIP R ,  LANE BENJAMIN C ,  PRATT JOHN K ,  VON GELDERN TOM ,  WINN MARTIN ,  PATEL JYOTI R ,  ARENDSEN DAVID L ,  AKRITOPOULOU-ZANZE IRINI ,  ASHWORTH KIMBA L ,  HARTANDI KRESNA ,  BRENNEMAN JEHROD

IPC: A61P3/10 ,  A61P7/12 ,  C07D311/80 ,  C07D407/04 ,  C07D409/04 ,  A61K31/352 ,  C07D405/04

CPC classification number: C07D407/04 ,  C07D311/80 ,  C07D409/04

Abstract: Compounds of formula (I) are useful for treating type (II) diabetes, obesity, hyperglycemia, inadequate glucose clearance, hyperinsulinemia, hypertriglyceridemia, and high-circulating glucocorticoid levels, preparations of the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract translation: 式（I）化合物可用于治疗II型糖尿病，肥胖症，高血糖症，葡萄糖清除率不足，高胰岛素血症，高甘油三酯血症和高循环性糖皮质激素水平，化合物的制剂，含该化合物的组合物，以及使用 化合物。

公开(公告)号：WO2010124042A3

公开(公告)日：2011-02-03

申请号：PCT/US2010031974

申请日：2010-04-22

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG ,  WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

Inventor： WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

IPC: C07D498/04 ,  A61K31/4985 ,  A61K31/551 ,  A61K31/553 ,  A61P25/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

CPC classification number: C07D498/04 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

Abstract: The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1,4]苯并二氮杂，1,2,3,4,4a， 7-八氢吡嗪并[1,2-a] [1,5]苯并二氮杂，2,3,4,4a，5,6,7,11b-八氢-1H-吡啶并[3,4-d] [2]苯并氮杂， 1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1]苯并氮杂，1,2,3,4,4a，5-六氢-7H-吡嗪并[1,2 -a] [4,1]苯并氧氮杂和2,3,4,4a，5,6-六氢-1H-吡嗪并[2,1-d] [1,5]苯并氧氮杂和5,6,7,7a ，其中R 1，R 2，R 3，R 4，R 5，R 6，R 6，R 5，R 6， X1，X2，X3，X4，Y1，Y2和Y3如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：NZ596827A

公开(公告)日：2014-01-31

申请号：NZ59682710

申请日：2010-05-20

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： WELCH DENNIE S ,  SHEKHAR SHASHANK ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  RELO ANA-LUCIA ,  TURNER SEAN C ,  GANDARILLA JORGE ,  WILSON NOEL S ,  GASIECKI ALAN F ,  ZHANG MIN ,  DJURIC STEVAN W ,  ZHAO HONGYU ,  KRUGER ALBERT W ,  THOMPSON CHRISTINA M ,  LI HUANQIU

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D225/00 ,  C07D491/04 ,  C07D495/04

Abstract: 596827 Disclosed is a compound of formula (I), such as (3aS,10bS)-8-chloro-2-methyl-1,2,3,3a,4,5-hexahydrobenzo[e]pyrrolo [3,4-c]azepin-6(10bH)-one and (3aS,10bS)-8-chloro-2-methyl-1,2,3,3a,4,5-hexahydrobenzo[e]pyrrolo [3,4-c]azepin-6(10bH)-one, which is useful for treating disorders associated with 5HT receptors. Also disclosed is a process for making such compounds.

公开(公告)号：HK1168853A1

公开(公告)日：2013-01-11

申请号：HK12109595

申请日：2012-09-28

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： WELCH DENNIE S ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: C07D20060101 ,  A61K20060101 ,  A61P20060101

公开(公告)号：MX2011012479A

公开(公告)日：2012-03-06

申请号：MX2011012479

申请日：2010-05-20

Applicant: ABBOTT LAB

Inventor： TURNER SEAN C ,  GASIECKI ALAN F ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  ZHANG MIN ,  DJURIC STEVAN W ,  GANDARILLA JORGE ,  SHEKHAR SHASHANK ,  WILSON NOEL S ,  RELO ANA-LUCIA ,  WELCH DENNIE S ,  KRUGER ALBERT W ,  ZHAO HONGYU ,  LI HUANQIU ,  THOMPSON CHRISTINA M

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D491/04 ,  C07D495/04

Abstract: La presente solicitud se refiere a derivados de decahidropirroloazepina fusionada a arilo- y heteroarilo, octahidrooxepinopirrol, dióxido de octahidropirrolotiazepina, decahidrociclohepta[c]pirrol, y octahidrociclohepta[cjpirrol de fórmula (I) (ver fórmula (I)) en donde R1, R2, R3, R4, R5, A, Y1, Y2, e Y3 son como se define en la especificación. La presente solicitud también se refiere a composiciones que comprenden tales compuestos, procesos para hacer tales compuestos, y métodos para tratar condiciones de enfermedad utilizando tales compuestos y composiciones y métodos para identificar tales compuestos.

公开(公告)号：CA2761961A1

公开(公告)日：2010-11-25

申请号：CA2761961

申请日：2010-05-20

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  WELCH DENNIE S ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D491/04 ,  C07D495/04

Abstract: The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I), wherein R1,R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：MX2009013213A

公开(公告)日：2010-03-30

申请号：MX2009013213

申请日：2008-06-04

Applicant: ABBOTT LAB

Inventor： KALVIN DOUGLAS M ,  WANG LU ,  GASIECKI ALAN F ,  GRACIAS VIJAYA J ,  AKRITOPOULOU-ZANZE IRINI ,  LI BIQIN ,  PATEL JYOTI R ,  SHUAI QI ,  TURNER SEAN C ,  DJURIC STEVAN W ,  BAKKER MARGARETHA ,  VASUDEVAN ANIL ,  MICHMERHUIZEN MELISSA J ,  SARRIS KATHY ,  HOBSON ADRIAN ,  TEUSCH NICOLE ,  MACK HELMUT ,  WAKEFIELD BRIAN D ,  JOHNSON ERIC T ,  KOVAR PETER J ,  LONG ANDREW J ,  MOORE NIGEL ST JOHN ,  GEORGE DAWN ,  FRANK KRISTINE

IPC: C07D403/04 ,  C07D413/04 ,  C07D417/04

Abstract: La presente invención se refiere a compuestos de la fórmula (I) o sales farmacéuticamente aceptables, en donde A, R1, R2, R3 y m, son como se definieron en la descripción. La presente invención se refiere también a métodos para elaborar los compuestos, y composiciones que contienen los compuestos los cuales son útiles para inhibir las cinasas tales como Glicógeno Cintaza cinasa 3 (GSK-3), Rho cinasa (ROCK), Janus Cinasas (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 y nek 2.

公开(公告)号：ES2423668T3

公开(公告)日：2013-09-23

申请号：ES10720502

申请日：2010-05-20

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG ,  ABBVIE INC

Inventor： WELCH DENNIE S ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D491/04 ,  C07D495/04

Abstract: Un compuesto de fórmula (I):**Fórmula** o una sal farmacéuticamente aceptable del mismo,donde A está seleccionado entre el grupo que consiste en R1, R3, R4, y R5 están seleccionados independientemente entre el grupo que consiste en hidrógeno, alquenilo, alquilo, haloalquilo, G1, G2, -(CR4aR5a)m-G1, y -(CR4aR5a)m-G2; R4a y R5a, en cada caso, cada uno es independientemente hidrógeno, halógeno, alquilo, o haloalquilo; G1, en cada caso, es independientemente arilo o heteroarilo, donde cada G1 está independientemente sin sustituir osustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, alquenilo, alquinilo,halógeno, ciano, -NO2, -OR1b, -OC(O)R1b, -OC(O)N(Rb)(R3b), -SR1b, -S(O)R2b, -S(O)2R2b, -S(O)2N(Rb)(R3b), -C(O)R1b,-C(O)OR1b, -C(O)N(Rb)(R3b), -N(Rb)(R3b), -N(Ra)C(O)R1b, -N(Ra)C(O)O(R1b), -N(Ra)C(O)N(Rb)(R3b), -(CR4bR5b)m-NO2,-N(Rb)S(O)2(R2b), -(CR4bR5b)m-OR1b, -C(OH)[(CR4bR5b)m-R4b]2, -(CR4bR5b)m-OC(O)R1b, -(CR4bR5b)m-OC(O)N(Rb)(R3b), -(CR4bR5b)m-SR1b, -(CR4bR5b)m-S(O)R2b, -(CR4bR5b)m-S(O)2R2b, -(CR4bR5b)m-S(O)2N(Rb)(R3b),-(CR4bR5b)m-C(O)R1b, -(CR4bR5b)m-C(O)OR1b, -(CR4bR5b)m-C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)(R3b), -(CR4bR5b)m-N(Ra)C(O)R1b, -(CR4bR5b)m-N(Ra)C(O)O(R1b), -(CR4bR5b)m-N(Ra)C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)S(O)2(R2b),cianoalquilo, y haloalquilo.

公开(公告)号：SG182187A1

公开(公告)日：2012-07-30

申请号：SG2012043113

申请日：2008-06-04

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： AKRITOPOULOU-ZANZE IRINI ,  WAKEFIELD BRIAN D ,  MACK HELMUT ,  TURNER SEAN C ,  GASIECKI ALAN F ,  GRACIAS VIJAYA J ,  SARRIS KATHY ,  KALVIN DOUGLAS M ,  MICHMERHUIZEN MELISSA J ,  SHUAI QI ,  PATEL JYOTI R ,  BAKKER MARGARETHA ,  TEUSCH NICOLE ,  KOVAR PETER J ,  DJURIC STEVAN W ,  LONG ANDREW J ,  VASUDEVAN ANIL ,  HOBSON ADRIAN ,  ST JOHN MOORE NIGEL ,  WANG LU ,  GEORGE DAWN ,  LI BIQIN ,  FRANK KRISTINE ,  JOHNSON ERIC T

Abstract: 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORSAbstractThe present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein A, R1,R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Ala, PAK4, PLK, CK2, KDR, MK2, JNK I, aurora, pim I and nek 2.No suitable figure

公开(公告)号：CA2759607A1

公开(公告)日：2010-10-28

申请号：CA2759607

申请日：2010-04-22

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

IPC: C07D498/04 ,  A61K31/4985 ,  A61K31/551 ,  A61K31/553 ,  A61P25/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

Abstract: The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.